Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. Gs-hiv Sodium
2. Bdt58wj9we
3. 2283356-12-5
4. Unii-bdt58wj9we
5. Gs-6207-02
6. Sunlenca
7. 1h-cyclopropa(3,4)cyclopenta(1,2-c)pyrazole-1-acetamide, N-((1s)-1-(3-(4-chloro-3-((methylsulfonyl)amino)-1-(2,2,2-trifluoroethyl)-1h-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)-1-butyn-1-yl)-2-pyridinyl)-2-(3,5-difluorophenyl)ethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-3-(trifluoromethyl)-, Sodium Salt (1:1), (3bs,4ar)-
8. N-((1s)-1-(3-(4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)-1h-indazol-7-yl)-6-(3-(methanesulfonyl)-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bs,4ar)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro1h-cyclopropa(3,4)cyclopenta(1,2-c)pyrazol-1-yl)acetamide, Sodium Salt (1:1)
9. Refchem:58517
10. Gs-hiv Na
11. Lenacapavir Sodium [usan]
12. Yeztugo
13. Sunlenca (tn)
14. Lenacapavir (sodium)
15. Lenacapavir Sodium [who-dd]
16. Orb2814823
17. Chembl4802249
18. Lenacapavir Sodium (jan/usan)
19. Schembl30612482
20. Schembl30685531
21. Ex-a5518a
22. Hy-111964a
23. D12162
| Molecular Weight | 990.3 g/mol |
|---|---|
| Molecular Formula | C39H31ClF10N7NaO5S2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 19 |
| Rotatable Bond Count | 13 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 164 |
| Heavy Atom Count | 65 |
| Formal Charge | 0 |
| Complexity | 2050 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 and 5. 1). Sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 and 5. 1).
J05AX
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
35
PharmaCompass offers a list of Lenacapavir Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Lenacapavir Sodium manufacturer or Lenacapavir Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lenacapavir Sodium manufacturer or Lenacapavir Sodium supplier.
A Lenacapavir Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lenacapavir Sodium, including repackagers and relabelers. The FDA regulates Lenacapavir Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lenacapavir Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lenacapavir Sodium supplier is an individual or a company that provides Lenacapavir Sodium active pharmaceutical ingredient (API) or Lenacapavir Sodium finished formulations upon request. The Lenacapavir Sodium suppliers may include Lenacapavir Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Lenacapavir Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Lenacapavir Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Lenacapavir Sodium active pharmaceutical ingredient (API) in detail. Different forms of Lenacapavir Sodium DMFs exist exist since differing nations have different regulations, such as Lenacapavir Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lenacapavir Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Lenacapavir Sodium USDMF includes data on Lenacapavir Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lenacapavir Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lenacapavir Sodium suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lenacapavir Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lenacapavir Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lenacapavir Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lenacapavir Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lenacapavir Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lenacapavir Sodium suppliers with NDC on PharmaCompass.
Lenacapavir Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lenacapavir Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Lenacapavir Sodium GMP manufacturer or Lenacapavir Sodium GMP API supplier for your needs.
A Lenacapavir Sodium CoA (Certificate of Analysis) is a formal document that attests to Lenacapavir Sodium's compliance with Lenacapavir Sodium specifications and serves as a tool for batch-level quality control.
Lenacapavir Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Lenacapavir Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lenacapavir Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Lenacapavir Sodium EP), Lenacapavir Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lenacapavir Sodium USP).